Home » Newsletters » BioWorld Science

BioWorld Science

July 12, 2017

View Archived Issues

MAX BioPharma obtains proof-of-concept data on Oxy-200 for osteoporosis

GeoVax's LASV vaccine candidate shows efficacy in animal model

FDA awards orphan drug status to Principia Biopharma's PRN-1008

Regulatory update for tucatinib in Europe

Unity Biotechnology patents Bcl-W, Bcl-XL and Bcl-2 inhibitors

Merck & Co. discloses Nav1.7 blockers

Bristol-Myers Squibb divulges apelin receptor agonists

Gilead Sciences patents TBK1 and IKK-E kinase inhibitors

Novartis presents guanylate cyclase activators

FDA issues complete response letter regarding Dextenza NDA

ViraCyte completes phase I study of Viralym-C

Nektar Therapeutics describes activity of autoimmune disease candidate NKTR-358

Daiichi Sankyo enters cancer reseach agreement with Max Planck and Lead Discovery Center

First-in-human results for inactivated influenza vaccine delivered by microneedle patch

First patient dosed in phase I study of ARQ-531

Novel TER ATPase inhibitor OSSL-325096 developed for treating multiple myeloma

CURE Pharmaceutical, Therapix to enter research collaboration with Assuta Medical Centers

MedigenixBio tests new antithrombotic compound MDI-2001 in vivo

FDA advisory committee votes in favor of Mylotarg for newly diagnosed AML

Amicus plans migalastat NDA for Fabry disease based on FDA communications

Xadago launched in U.S.

FDA grants full approval to Blincyto for B-cell precursor ALL

First-in-human study finds TFPI inhibitor PF-06741086 well tolerated

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...